INTERNATIONAL research into the impacts of a first-of-its-kind GLP-1 pill were revealed this weekend in the New England Journal of Medicine and at the American Diabetes Association's annual conference in Chicago.
The tablet, known as orforglipron, is taken orally once daily by patients with poorly controlled type 2 diabetes, and works to mimic GLP-1, a natural hormone which plays a crucial role in regulating blood sugar and appetite.
The study compared the efficacy and safety of Eli Lilly's GLP-1 agonist with placebo in more than 500 adults living with type 2 diabetes whose blood glucose levels were inadequately controlled with diet and exercise alone.
The pill became the first oral small molecule (non-peptide) GLP-1 agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial.
Eli Lilly intends to share the findings from the study with the Therapeutic Goods Administration to make it available for eligible Australians with type 2 diabetes.
The company is also conducting additional research into the role orforglipron may play in the management of type 2 diabetes that is inadequately controlled with other therapies, as well as in the treatment of obesity and other metabolic conditions.
"For over 100 years, Lilly has been at the forefront of diabetes innovation and care to support the health and wellbeing of people with diabetes," Eli Lilly General Manager Tori Brown declared.
"These clinically meaningful findings will accelerate the momentum generated by the research and real-world use of injectable medicines that activate key hormones to regulate blood sugar and appetite," she added. MS
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jun 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jun 25
